Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
758 studies found for:    Cetuximab
Show Display Options
Rank Status Study
1 Completed
Has Results
A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Head and Neck Cancer;   Squamous Cell Carcinoma
Interventions: Drug: Cetuximab;   Drug: Bevacizumab
2 Recruiting Regorafenib and Cetuximab in Patients With Advanced Malignancy
Condition: Advanced Cancers
Interventions: Drug: Regorafenib;   Drug: Cetuximab;   Behavioral: Questionnaire
3 Completed Phase 1 and 2 Study of PX-866 and Cetuximab
Conditions: Incurable Metastatic Colorectal Carcinoma;   Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: PX-866 (SCCHN);   Drug: Cetuximab (SCCHN);   Drug: PX-866 (CRC);   Drug: Cetuximab (CRC)
4 Completed
Has Results
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
Conditions: Colorectal Cancer;   Squamous Cell Head and Neck Cancer;   Non-small Cell Lung Cancer;   Triple Negative Breast Cancer;   Other Tumors With EGFR Dependence
Interventions: Drug: MM-121;   Drug: Irinotecan;   Drug: Cetuximab
5 Recruiting Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid or Cetuximab in Patients With Advanced Malignancy and Other Indications
Condition: Advanced Cancers
Interventions: Drug: Temsirolimus;   Drug: Bevacizumab;   Drug: Valproic Acid;   Drug: Cetuximab
6 Recruiting Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Condition: Squamous Cell Carcinoma
Interventions: Drug: Cisplatin;   Radiation: IMRT;   Drug: Docetaxel;   Drug: Cetuximab
7 Active, not recruiting Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Conditions: Carcinoma, Squamous Cell of Head and Neck;   Squamous Cell Carcinoma of the Head and Neck;   Squamous Cell Carcinoma, Head And Neck
Interventions: Drug: Ficlatuzumab;   Drug: Cetuximab
8 Completed Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)
Conditions: Colorectal Cancer;   Liver Metastases
Interventions: Drug: Cetuximab;   Procedure: Liver resection;   Drug: Cetuximab and FOLFIRI;   Drug: Cetuximab and FOLFOX
9 Withdrawn Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib
Condition: Advanced Cancers
Interventions: Device: SIR-Spheres;   Drug: Cetuximab;   Drug: Erlotinib;   Procedure: Break-Through Scan
10 Recruiting Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer
Conditions: Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Verrucous Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Verrucous Carcinoma of the Larynx;   Tongue Cancer
Interventions: Biological: cetuximab;   Drug: cisplatin;   Radiation: external beam radiation therapy;   Other: laboratory biomarker analysis
11 Withdrawn Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE)
Condition: Squamous Cell Carcinoma of the Penis
Interventions: Drug: Cetuximab;   Drug: TIP
12 Recruiting Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
Conditions: Thymoma;   Thymic Carcinoma;   Clinical Masaoka Stage II to IVA
Intervention: Drug: Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
13 Recruiting Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Dose escalation cetuximab;   Drug: Standard dose cetuximab
14 Completed Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Intervention: Drug: Cetuximab
15 Completed Erlotinib in Combination With Cetuximab
Condition: Advanced Cancers
Interventions: Drug: Erlotinib;   Drug: Cetuximab
16 Active, not recruiting Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Drug: Dose escalation of cetuximab;   Drug: Standard first line treatment with cetuximab + Folfiri
17 Active, not recruiting ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Cetuximab;   Procedure: Surgery;   Radiation: Post-surgical radiation;   Drug: Cisplatin or carboplatin
18 Completed
Has Results
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer
Condition: Head and Neck Cancer
Interventions: Biological: Cetuximab;   Drug: Carboplatin;   Drug: Paclitaxel;   Radiation: Radiation therapy
19 Completed Sirolimus and Cetuximab in Advanced Malignancies
Condition: Advanced Cancer
Interventions: Drug: Sirolimus;   Drug: Cetuximab
20 Recruiting Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer
Condition: Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions: Drug: palbociclib;   Drug: Cetuximab;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years